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ORIGINAL AND CLINICAL ARTICLES
Sepsis is a syndrome of physiological, patho-
logical, and biochemical abnormalities, with 
several pathophysiological processes that occur 
simultaneously [1]. The worldwide incidence of 
sepsis is increasing [2–6], and therefore the correct 
understanding of its pathophysiology, diagnosis, 
and treatment are important. Depending on the 
definition used, incidence in the United States var-
ies between 300 per 100,000 and 1031 per 100,000 
inhabitants, with an annual growth of 13% [4]. Hos-
pital mortality varies between 14.7% and 29% [4]. In 
some studies, carried out in Latin-America, it is even 
higher [7–10].
Among the pathophysiological processes, 
mitochondrial dysfunction, which is caused by 
a decreased function of certain complexes in the 
electron transport chain, producing less energy 
and higher levels of free radicals, can be found. 
In vivo, reactive oxygen species (ROS) are produced 
in different pathways, different cells, and in different 
quantities. In severe pathologies, phagocytes are 
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the main cells that produce ROS as an element of im-
mune defence, and their purpose is the destruction 
of microorganisms. Under normal circumstances, 
there is a continuous production of small amounts 
of ROS in the mitochondria and, more precisely, in 
the electron transport chain [11]. It is believed that 
the latter is responsible for 90% of ROS produced in 
the cell [12, 13]. Immune system and mitochondrial 
dysfunction are the main sources of ROS. In sepsis, 
ROS and reactive nitrogen species (RNS) are in-
creased, both in circulation and in tissue [14].
The plasma oxidative burst takes place in the 
early stages of sepsis and is carried out by neutro-
phils, macrophages, and endothelial cells. Antioxi-
dants remove ROS from the plasma, which leads to 
a decrease in the concentration of these molecules 
[15]. The level of free thiols decreases due to oxi-
dation or nitrosylation [15]. As a result, the level 
of antioxidant capacity of plasma is reduced [15]. 
There are several proteins that activate signalling 
pathways that promote apoptosis and are sensitive 
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Abstract
Background: Oxidative stress is one of the pathophysiological processes that occur 
during sepsis. Reactive oxygen species (ROS) production causes lipid peroxidation and 
protein and DNA damage. ROS and DNA damage triggers apoptosis. Several studies 
have shown that organ failure in sepsis is mediated by apoptosis. The aim of this study 
is to investigate the levels of serum ROS and serum caspase-3 in septic patients and 
healthy volunteers, and their correlation.
Methods: Serum samples were taken within the first 12 hours of ICU stay. The dichlo-
rofluorescein technique was used to determine serum ROS levels, and the ELISA tech-
nique was used to quantify serum caspase-3 in septic patients and healthy volunteers.
Results: There was no difference in serum ROS levels between healthy volunteers and 
septic patients (P = 0.26), and there was a significant difference in serum caspase-3 
levels between healthy volunteers and septic patients (P < 0.001). There was no differ-
ence between patients who lived and died in the intensive care unit (ICU) in serum ROS 
(P = 0.089) and serum caspase-3 (P = 0.18). There was no correlation between both 
markers (R = –0.0013, P = 0.98).
Conclusions: We conclude that there is no correlation between serum ROS and caspase-3; 
therefore, both processes might not be associated during the first hours of ICU stay. 
Key words: reactive oxygen species, apoptosis, caspase, sepsis.
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to superoxide [16]. Also, hydroxyl radical is a reac-
tive species that oxidizes lipids, proteins, and DNA, 
which results in genomic instability [17].
On the other hand, another pathophysiological 
process described in sepsis is apoptosis. Apoptosis 
is a highly regulated and conserved cell death pro-
cess during which the cell self-destructs [16]. It is 
a normal process, which, in multicellular organisms, 
eliminates undesired or superfluous cells, neutral-
izing the potential damage caused by cells with de-
fective DNA [16].
Cells in which apoptosis is triggered decrease in 
size and are condensed and fragmented, releasing 
membrane-limited apoptotic bodies that are gener-
ally absorbed by other cells [18]. In addition, the nu-
cleus is condensed, the DNA is fragmented, and the 
cellular constituents are not released to the extracel-
lular medium where they could harm the surrounding 
cells, in contrast with what happens in cell death by 
necrosis [18]. Apoptosis involves enzymes that cleave 
proteins at the cysteine amino acid level (caspases) 
[18]. Most, but not all, of the apoptotic pathways lead 
to the activation of these enzymes [16].
Different triggers have been proposed as the 
cause of organ failure: Decreased tissue perfusion 
and its resulting respiratory failure, mitochondrial 
dysfunction, the production of ROS, and other 
mecha nisms, cell death being the final outcome [19].
In recent years, interest in apoptosis as a mecha-
nism of cell death has increased. There are studies 
that show increased levels of apoptosis at the cel-
lular level in different models of sepsis [20–23], 
but there is insufficient evidence regarding sys-
temic apoptosis levels in septic patients, or the 
relationship with mortality in intensive care units 
(ICU) [24, 25]. While several organs show evidence 
of inflammation with migration of inflammatory 
cells, increased interstitial fluid, increased capillary 
permeability, and epithelial disruption, the degree 
of cell death is low [26]. The degree of cell death is 
disproportionately low compared with the degree 
of clinical severity or the biochemical presentation 
of organ dysfunction [26, 27]. Also, there is indirect 
evidence of lymphocyte apoptosis in septic patients 
with extensive depletion of lymphocytes in the 
white pulp of the spleen [28].
Both pathophysiological processes (ROS produc-
tion and apoptosis) and others like inflammation, 
thrombosis, microabscess formation, and ischaemic 
changes are causes of the multiple organ dysfunc-
tion observed in sepsis, which, if left uncontrolled, 
leads to patient death [29]. The aim of this study was 
to investigate the level of serum markers of ROS and 
apoptosis and to ascertain whether those processes 
occur simultaneously. There is no literature relating 
ROS levels and apoptosis in sepsis.
METHODS
Study design
This is a prospective observational trial, carried 
out in a single centre. The centre is a private tertiary 
hospital with an intensive care unit with 27 beds, 
in Buenos Aires, Argentina. Subjects were included 
between May 2013 and December 2017. The pro-
tocol was approved by the local internal review 
board (number of approval: CRIHB#521). All patients 
signed an informed consent form.
Inclusion and exclusion criteria
Inclusion criteria for the patients were as follows: 
aged between 18 and 80 years with a diagnosis of 
sepsis, according to the Sepsis-2 definition [30]. 
Inclusion criteria for the healthy volunteers were as 
follows: over 18 years of age with no actual septic 
pathology or signs. Exclusion criteria for the septic 
patients were the following: refusal of informed 
consent, limitation of therapeutic efforts at the time 
of inclusion in the study, and pregnancy.
Treatment of sepsis
The diagnosis and treatment of sepsis was de-
cided by ICU physicians. For treatment, the recom-
mendations of the 2013 and 2016 “Surviving Sepsis 
Campaign” guides were followed [2, 31].
Measurement of serum reactive oxygen 
species
Upon arrival of the patient, within 12 hours of 
admission to the ICU, venous blood samples were 
taken. After that, blood was centrifuged for 5 min-
utes at 3000 rpm, and serum was frozen at –70°C, 
as described in the bibliography [32–34]. Using di-
chlorofluorescein-diacetate (DCFH) (Sigma Aldrich. 
Catalogue D6665) ROS were measured. 12 µL of se-
rum were incubated for 10 minutes in 1000 µL of 
TE buffer, and 10 µL of NaOH and 10 µL of DCFH 
solution were added. Fluorescence was measured 
after creating an emission spectrum between 500 
and 550 nm with each serum sample; the peak of 
emission at 525 nm was recorded.
Measurement of serum levels  
of caspase-3
In the same sample described for the measure-
ment of serum ROS, the quantification of caspase-3 
levels was carried out using the ELISA method on 
patients’ serum. The kit was manufactured by My-
BioSource® – Human Caspase-3 ELISA KIT Catalogue 
#MBS040290, batches #02/2016 and #10/2017. In or-
der to do this, the patients’ serum, frozen at –70°C, was 
used. The levels of caspase-3 are shown in pg mL–1. 
Samples were measured using an EMP M201® Micro-
plate Reader (China).
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Statistical analysis
Normal and non-normal distribution data were 
determined based on mean, median, and kurtosis. 
The mean was calculated with standard deviation 
(SD) to describe quantitative variables in normal 
distribution data, and with 95% confidence inter-
val (95% CI) in non-normal data. In order to analyse 
whether there were significant differences in con-
tinuous variables between two groups, Student’s 
t-test was used for variables with normal distri-
bution, and the U Mann-Witney test was used for 
variables with abnormal distribution. To compare 
nominal and ordinal qualitative variables, the chi-
square test was used. To correlate two variables, the 
Spearman test was used, depending on whether the 
distribution of the variables was normal or not. In 
all cases, a significance level of P < 0.05 was consid-
ered. The following statistical programs were used: 
EPIinfo 7.0, Statistix 7.0 (Informer Technologies, Inc., 
Atlanta, USA), and Graph Pad Prism 8.0.2. (Graph-
Pad Software, San Diego, USA).
RESULTS
Table 1 shows the comparison of demographic 
and clinical parameters between patients and 
healthy volunteers. A total of 124 people were en-
rolled, 98 of whom were patients with severe sep-
sis or septic shock diagnoses, and 26 were healthy 
volunteers. None of the healthy volunteers had 
a chronic disease that required treatment. The 
healthy volunteers were younger than the patients. 
Table 2 describes the severity of disease scores and 
origin of infection.
Serum ROS were measured using the DCFH 
technique. There were no differences in the ROS 
levels between healthy volunteers and septic pa-
tients (Emission = 0.1077 [SD = 0.0324] vs. 0.108 
[SD = 0.0364]; P = 0.26) (Figure 1A). Twenty-eight 
out of the 98 patients died during hospitalization. 
When analysing only septic patients, there were 
no differences in the ROS levels of patients who 
survived and those who died in the ICU (Emission 
= 0.1103 [SD = 0.0384] vs. 0.1022 [SD = 0.0303]; 
P = 0.089) (Figure 1B). Finally, 7 patients died during 
the first day of hospitalization, and there were no 
differences between those patients and the patients 
who survived (Emission = 0.1076 [SD =0.0369] vs. 
0.1145 [0.029]; P = 0.31) (Figure 1C).
Serum levels of caspase-3 were higher than 
those of healthy volunteers (31.75 pg mL-1 [95% CI: 
25.84–37.65] vs. 7.67 pg mL-1 [95% CI: 1.93–13.4]; 
P < 0.001) (Figure 2A). When analysing only pa-
tients, there were no statistically significant dif-
ferences between patients who lived and those 
who died during their hospitalization in the ICU 
(28.49 pg mL-1 [95% CI: 22.21–34.77] vs. 39.89 pg mL–1 
[95% CI: 26.22–53.57]; P = 0.18) (Figure 2B). Finally, 
there were no significant differences in the levels 
of caspase-3 between patients who survived and 
those who died on the first day (29.83 pg mL–1 
[95% CI: 23.99–35.67] vs. 56.69 pg mL-1 [95% CI: 
21.82–91.56]; P =0.1) (Figure 2C).
The Spearman test was performed to dem-
onstrate any correlation between DCFH emission 
levels and serum levels of caspase-3 of septic pa-
tients and those of healthy volunteers. There was 
no correlation between the levels of both variables. 
A scatter plot with levels of both variables was made 
(Figure 3). In addition, the Spearman test was also 
performed to demonstrate any correlation between 
DCFH emission levels and serum levels of caspase-3 







Age, years 49 64.38 < 0.001
Sex (male/female), n 11/15 56/42 0.25
Tobacco use, n 2 56 < 0.001
Diabetes, n 2 54 < 0.001
Hypertension, n 2 48 < 0.001
Dyslipidaemia, n 3 18 0.56
Ischemic cardiopathy, n 0 15 0.038
Heart failure, n 0 6 0.34
COPD, n 0 9 0.20
Atrial fibrillation, n 0 9 0.20
Chronic kidney disease, n 0 13 0.06
Rheumatic disorder, n 0 8 0.20
Oncologic disease, n 0 24 0.002
Oncohaematological disease, n 0 11 0.45
HIV, n 0 2 1
The c2 and Student tests were used to determine whether there were differences between the groups.
TABLE 2. Description of the septic patient population. The charac-
teristics of the septic patient population are described. The APACHE II 
score values were taken with the worst result in the first 24 hours 
and the SOFA score with the values at admission





Skin and muscle 9 (9.28)
Neurological 2 (2.06)
Other 6 (6.19)
APACHE II 17.35 (SD: 7.26)
SOFA 7.33 (SD: 3.11)
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FIGURE 1. Serum reactive oxygen species (ROS) levels. A) ROS levels in healthy volunteers and patients. Dichlorofluorescein-diacetate (DCFH) emission levels 
are stated at 525 nm as a marker of ROS. There was no significant difference between groups. Student’s test (P = 0.26). B) ROS levels of patients who lived 
and died in the ICU. DCFH emission levels are stated at 525 nm as a marker. There was no significant difference between groups. Student’s test (P = 0.089). 
C) ROS levels in septic patients who lived and those who died on the first day of hospitalization. DCFH emission levels are stated at 525 nm as a marker of 
ROS. There was no significant difference between groups. Student’s test (P = 0.31)
FIGURE 2. Serum apoptosis levels. A) Serum levels of Caspase-3 in healthy volunteers and septic patients. There were significant differences between groups 
when using the Mann Whitney test (P < 0.001). B) Serum levels of Caspase-3 in patients who lived and those who died in the ICU. There were no significant 
differences between groups. Mann Whitney test (P = 0.18). C) Serum levels of Caspase-3 in patients who lived and those who died during the first day of 







only among septic patients. There was no correla-
tion between the levels of both variables. A scatter 
plot with levels of both variables was constructed 
(Figure 4).
Finally, correlation between serum ROS and 
serum caspase-3 levels with the severity scores 
SOFA and APACHE II was also analysed. There was 
no correlation between the levels of caspase-3 and 
the SOFA score (R = 0.1823; P = 0.08), nor with the 
APACHE II score (R = 0.1047; P = 0.32). There was also 




















































































Non survivor day 1
Non survivor day 1
FIGURE 3. Correlation between reactive oxygen species (ROS) levels and serum levels 
of caspase-3. ROS were measured using the dichlorofluorescein-diacetate (DCFH) 
technique and serum levels of caspase-3 were measured in healthy volunteers and 
controls. There was no correlation between both variables (R = –0.0013, P = 0.98)
levels (R = –0.0562; P = 0.6). In contrast, there was 
an inverse correlation between SOFA levels and ac-
tivated ROS levels (R = –0.2146; P = 0.04).
DISCUSSION
In this study, we included 98 septic patients and 
26 healthy volunteers. All patients were admitted to 
the ICU with severe sepsis and septic shock diag-
noses, in accordance with the second definition of 
sepsis, which was valid at the start of the study [30]. 
However, considering the Sepsis-3 consensus [1], 
the same group of patients would have been in-
cluded. This study is innovative because a group of 
healthy volunteers were included, and serum ROS 
and caspase-3 levels were obtained from them.
It was noted that there were no differences in 
systemic ROS levels between healthy volunteers 
and septic patients, and no differences between 
septic patients who died ICU and those who sur-
vived. Moreover, there were no differences between 
patients who died during the first day of hospital-
ization and those who survived. These results are 
not in accordance with those obtained in previous 
studies performed on rats, in which the septic group 
had higher ROS levels than the control group, using 
the same technique to measure ROS [35]. These dif-
ferences may be due to methodological issues be-
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had sepsis for 24 h, while patients in the hospital 
came in through the emergency service, they were 
supported with fluids, the first dose of antibiotics 
was administered, then they were admitted to the 
ICU, a central line was placed, they were intubated 
if necessary, vasoactive drugs were administered, 
and finally the samples were taken. Another pos-
sible cause for this difference between the results 
obtained from rats and those from patients is that 
they are different models, with a different patho-
physiologies, and therefore it is often difficult to 
replicate animal results in patients [15, 29].
This study is innovative because serum ROS 
were measured in septic patients instead of oxida-
tive stress markers. Previous literature associated 
damage at the tissue level with ROS [36–41]. Using 
the current technique, ROS levels in yeast were mea-
sured under stress conditions with Menadione [42]. 
The DCFH technique is an already described tech-
nique to measure intracellular ROS also in extracel-
lular fluids [43–46]. It has been demonstrated in our 
laboratory that septic rats have higher levels of ROS 
than controls, and that the administration of paren-
teral succinate decreases ROS levels [35].
In several models, it has been shown that ROS 
damage cell structures including DNA, which leads 
to apoptosis. The presence of serum ROS in an ani-
mal model of sepsis are also increased, but this is not 
associated with markers of organ failure [47]. Lorente 
et al. [48] showed that the total antioxidant capac-
ity of septic patients who did not survive was higher 
and, in turn, this was a marker of 30-day mortality. 
Also, septic patients with a SOFA score higher than 
7 had higher ROS levels measured with DCFH [49].
DCFH emission results and corresponding serum 
ROS levels in septic patients are not in accordance 
with studies that measure oxidative stress, prob-
ably because different techniques are used. In this 
study, DCFH emission that states serum ROS levels 
was measured, while in other studies, either antioxi-
dant capacity or oxidative stress substitutes, such as 
TBARS or oxidized proteins, were measured.
On the other hand, apart from the measurement 
of ROS and oxidative stress markers, multiple stud-
ies with antioxidants have been carried out. Preclini-
cal and clinical trials with antioxidants had diverse 
results. In a preclinical murine model of sepsis, cir-
culating cytokines, increased urea, ALT, and LDH, 
decreased glucose, lymphopaenia/neutrophilia, and 
NO blood release were not altered with the treat-
ment with SkQ1 antioxidants, and there was no 
difference in survival with antioxidant mtAOX [50]. 
Other preclinical trials had positive results. Superox-
ide dismutase (SOD), catalase (CAT), and ascorbate 
peroxidase (APX) activities were decreased after the 
administration of antioxidant quercetin in septic 
rats [51]. In rats that were injected intraperitoneally 
with lipopolysaccharide, it was observed that pre-
treatment with N-acetylcysteine (NAC) decreased 
certain parameters of oxidative stress [52, 53]. Also, 
in a study with septic rats, the administration of in-
traperitoneal NAC, associated with deferoxamine, 
decreased the production of superoxide, the activity 
of enzyme catalase, superoxide dismutase, and my-
eloperoxidase in all organs, in addition to improving 
survival [54]. In several clinical trials in which septic 
patients were supplemented with antioxidants, the 
length of mechanical ventilation or oxygen levels 
were not reduced [55–68]. There are many works 
that describe differences between animal models 
of sepsis and patients, and the difficulty of trans-
ferring the results of the animal model to patients 
[69–71]. The absence of positive results in clinical 
studies with antioxidants has some sort of relation-
ship with the results of the current study, in which 
there were no differences between the ROS levels of 
healthy volunteers and septic patients.
In addition, septic patients had higher serum 
levels of caspase-3 than healthy volunteers, with 
statistically significant differences. The median se-
rum levels of caspase-3 in patients who died was 
75% higher than in those who survived, but the dif-
ferences were not statistically significant. Similarly, 
the median of patients who died on the first day was 
90% higher than those who survived the first day, 
but these differences were not statistically signifi-
cant. This is due to the statistical test chosen and the 
spread of data with a large confidence interval width 
[72], but it does not make the data less relevant [73].
When comparing the data obtained with those 
from the literature, there are certain similarities. In 
a study carried out by Lorente et al. [74] a higher 
mortality in septic patients with higher serum levels 
of caspase-3 measured using the ELISA technique 
was shown. In this study, higher caspase-3 levels 
FIGURE 4. Correlation between systemic reactive oxygen species (ROS) levels and 
serum levels of caspase-3 in septic patients. There was no correlation between both 
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are associated with higher mortality (odds ratio, 
6.51; 95% CI: 3.32–12.77; P < 0.001) [74]. In the same 
study, a positive correlation between caspase-3 and 
a different marker of apoptosis, caspase-cleaved 
cytokeratin-18, was found [74]. The same group 
published a study in which caspase-cleaved cyto-
keratin-18 was higher in septic patients who died in 
the ICU and had a positive correlation with levels of 
interleukin 6, APACHE II, SOFA, and lactate [75]. Simi-
larly, this research group found that higher levels of 
caspase-cleaved cytokeratin-18 (levels over 20 UI L-1) 
resulted in higher mortality (OR = 8.476; 95% CI: 
2.087–34.434; P = 0.003) [76]. Although these results 
contrast with those obtained in the present work, 
it should be taken into account that patients were 
different, and the laboratory tests to measure serum 
caspase were different. These are possible explana-
tions for these differences in the results.
Also, this study is innovative because it was 
noted that there was no correlation between se-
rum levels of ROS and caspase-3 between healthy 
volunteers and septic patients. Nor was there a cor-
relation between serum levels of ROS and caspase-3 
when analysing only the patient group. This is an 
interesting finding, which suggests that there is no 
association between those molecular processes 
in sepsis. No other study in the bibliography that 
quantified ROS and apoptosis markers was found. 
ROS are molecules with a very short life. A limita-
tion of this study is that samples were taken in the 
ICU, after a central line was placed and vasoactive 
drugs were indicated. More studies with samples 
taken at hospital admission and different times of 
stay should be performed to clarify this finding.
Finally, it should be clarified first that, although 
the recruitment time was relatively long, the condi-
tions remained the same during the study and all 
patients were treated by the same medical team, al-
though the therapies could have changed slightly 
in that period. Second, only ROS were measured 
in serum; other measurements could have been 
carried out (i.e. carbonylated proteins or TBARS), 
but the objective was to observe the effect of the 
relationship between these chemical species and 
mortality, as well as their relationship with apopto-
sis markers. Finally, it should be considered that the 
severity of the patients’ disease was very heteroge-
neous, because obtaining the largest possible num-
ber of cases was deemed more important than the 
homogeneity of the sample. A more homogeneous 
sample could have generated other results.
CONCLUSIONS
In the present work, serum ROS levels were mea-
sured, and septic patients did not show higher se-
rum ROS levels than healthy volunteers. Conversely, 
patients showed higher serum levels of caspase-3 
than healthy volunteers. There was no correlation 
between the serum levels of both markers. These 
results would indicate that serum ROS do not serve 
as markers of oxidative stress in septic patients, de-
spite the fact that ROS production is known to take 
place at the tissue level, but instead, serum apop-
tosis markers could reveal the occurrence of cellu-
lar damage and consequent multi-organ failure in 
these patients relatively fast and with ease.
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